David Rintell, Ed.D.
Head of Patient Advocacy, BridgeBio
Dr. David Rintell currently serves as the Head of Patient Advocacy at BridgeBio, a role he has held since November 2017, where he focuses on actively involving patients, families, and caregivers in the drug development process.
Before joining BridgeBio, Dr. Rintell was the Head of Global Patient Advocacy for Rare Diseases at Sanofi Genzyme, fostering partnerships with patient communities. His professional experience includes roles as an Adjunct Professor at Brandeis University and as a psychologist at the Partners Multiple Sclerosis Center and Partners Pediatric Multiple Sclerosis Center.
Additionally, Dr. Rintell has contributed to the Foundation for Neurologic Diseases and served on the Clinical Advisory Committee for the National MS Society. He holds an Ed.D. in Counseling Psychology from Boston University.